Antibody-drug conjugates (ADCs): all 1,111 studies that test it

Page 3 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.

• DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingNCT06989112Phase 3
• Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingNCT06985485Phase 2
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Phase 3
• Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerNot yet recruitingNCT06957561Phase 1/2
• Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruitingNCT06952660Phase 4
• A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingNCT06952504Phase 3
• A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06944496Phase 3
• A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)RecruitingNCT06941272Phase 1/2
• A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerRecruitingNCT06926920Phase 1/2
• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)RecruitingNCT06925737Phase 3
• Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)RecruitingNCT06923826Phase 2
• Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaRecruitingNCT06919939Phase 2
• Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy FailureRecruitingNCT06918912Phase 2
• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingNCT06917911Phase 2
• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Phase 3
• A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaRecruitingNCT06891560Phase 2
• A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingNCT06890338Phase 2
• A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast CancerRecruitingNCT06878625Phase 2
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingNCT06863272Phase 1/2
• A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerRecruitingNCT06862219Phase 4
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3
• A Study of PHST001 in Advanced Solid TumorsRecruitingNCT06840886Phase 1
• Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingNCT06837792Phase 2
• A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingNCT06831370Phase 4
• A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)RecruitingNCT06824467Phase 3
• A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)RecruitingNCT06822543Phase 2
• Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)RecruitingNCT06819007Phase 3
• Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingNCT06809140Phase 2
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Phase 3
• First-in-Human Study of ADCE-D01 in Soft Tissue SarcomaRecruitingNCT06797999Phase 1/2
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingNCT06797635Phase 2
• A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the ScrotumRecruitingNCT06791070Phase 2
• Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)RecruitingNCT06788964Phase 2
• A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)RecruitingNCT06780137Phase 1/2
• Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Phase 1/2
• Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)RecruitingNCT06780098Phase 2
• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingNCT06764875Phase 3
• Trial of Trastuzumab Deruxtecan in Previously Treated HER2RecruitingNCT06750484Phase 2
• Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expressionRecruitingNCT06749860Phase 2
• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
• Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerRecruitingNCT06734182Phase 2
• A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast CancerNot yet recruitingNCT06733233Phase 2
• A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingNCT06731907Phase 2
• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Phase 3
• First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Phase 2
• Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLCNot yet recruitingNCT06706219Phase 2
• Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingNCT06686394Phase 1/2
• A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab SoravtansineRecruitingNCT06682988Phase 2
• Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceRecruitingNCT06682728Phase 2
• Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyRecruitingNCT06680596Phase 2
• A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)RecruitingNCT06679101Phase 3
• First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+TrodelvyRecruitingNCT06667167Phase 2
• Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast CancerRecruitingNCT06665178Phase 2
• RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment FailureRecruitingNCT06663007Phase 1/2
• Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.RecruitingNCT06660511Early Phase 1
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Phase 3
• A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingNCT06643585Phase 3
• Perioperative Therapies in Locally Advanced Unresectable Gastric CancerRecruitingNCT06630130Phase 2
• Castrate Resistant Prostate Cancer Enhertu TherapyRecruitingNCT06610825Phase 2
• Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)RecruitingNCT06607549Phase 1
• Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell LymphomaRecruitingNCT06594939Phase 2
• Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian CancerNot yet recruitingNCT06574763Phase 2
• A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06568939Phase 2
• Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT AssessmentRecruitingNCT06563245Phase 2/3
• A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.RecruitingNCT06561555Phase 2
• Neoadjuvant Therapy in Cervical CancerRecruitingNCT06558682Not applicable
• Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLRecruitingNCT06554626Phase 2
• A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
• Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCCRecruitingNCT06553885Phase 2
• T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingNCT06548178Phase 2
• TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdRecruitingNCT06533826Phase 2
• Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2
• A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingNCT06524544Phase 3
• The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
• A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
• A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingNCT06508216Phase 1/2
• RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerNot yet recruitingNCT06492317Phase 2
• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingNCT06486883Phase 2
• T-DM1 Combined With CDK4/6 Inhibitor RibociclibEnrolling by invitationNCT06481956Phase 2
• A Study of Sacituzumab Govitecan in People With MesotheliomaRecruitingNCT06477419Phase 2
• Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingNCT06470282Phase 1/2
• Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Phase 1/2
• Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLEnrolling by invitationNCT06468943Phase 2
• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingNCT06467357Phase 3
• Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast CancerRecruitingNCT06462092Phase 1/2
• Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain MetastasesNot yet recruitingNCT06462079Phase 2
• Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular LymphomaRecruitingNCT06453044Phase 2
• Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.RecruitingNCT06450314Phase 2
• Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingNCT06445972Phase 1/2
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)RecruitingNCT06434350Phase 1/2
• Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.RecruitingNCT06431633Phase 3
• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)RecruitingNCT06428409Phase 1/2
• Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingNCT06427330Phase 2
• Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Phase 3
• A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid TumorsRecruitingNCT06417554Phase 1/2
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
• Sacituzumab Govitecan and Bevacizumab for NSCLC Brain MetastasesRecruitingNCT06401824Phase 2

← Antibody-drug conjugates (ADCs) overview